Variable renal disease progression in autosomal dominant polycystic kidney disease: A role for nitric oxide?

Journal of Nephrology

Volumn 16, Issue 3, 2003, Pages 449-452

  Devuyst, Olivier ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Endothelium; Modifying genes; Nitric oxide; Polycystic kidney disease

Indexed keywords

ARGININE; CITRULLINE; CYCLIC GMP; GUANOSINE TRIPHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; POLYCYSTIN;

AUTOSOMAL DOMINANT DISORDER; CONFERENCE PAPER; DISEASE COURSE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME REGULATION; EXPERIMENTAL MODEL; GENE LOCUS; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MOUSE; MOUSE STRAIN; NONHUMAN; SIBLING; TWINS; VASCULAR SMOOTH MUSCLE;

ANIMALS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY DISEASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC;

EID: 0038127260     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Walker D, Consugar M, Slezak J, Rossetti S, Torres VE, Winearls CG, Harris PC. The ENOS polymorphism is not associated with severity of renal disease in polycystic kidney disease 1. Am J Kidney Dis 2003; 41: 90-4.
2. Devuyst O, Persu A, Stoenoiu MS, Lens X, Chauveau D, Pirson Y. ENOS polymorphism and renal disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2003; 41: 1124-5.
3. Peters DJ, Breuning MH. Autosomal dominant polycystic kidney disease: Modification of disease progression. Lancet 2001; 358: 1439-44.
4. Hateboer N, Van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999; 353: 103-7.
5. Rossetti S, Burton S, Strmecki L, Pond GR, San Millan JL, Zerres K, Barratt TM, Ozen S, Torres VE, Bergstralh EJ, Winearls CG, Harris PC. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol 2002; 13: 1230-7.
6. Pei Y. A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001; 7: 151-6.
7. Dipple KM, McCabe ER. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol Genet Metab 2000; 71: 43-50.
8. Woo DD, Nguyen DK, Khatibi N, Olsen P. Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 1997; 100: 1934-40.
9. Kuida S, Beier DR. Genetic localization of interacting modifiers affecting severity in a murine model of polycystic kidney disease. Genome Res 2000; 10: 49-54.
10. Wu G, Tian X, Nishimura S, Markowitz GS, D'Agati V, Park JH, Yao L, Li L, Geng L, Zhao H, Edelmann W, Somlo S. Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet 2002; 11: 1845-54.
11. Levy M, Duyme M, Serbelloni P, Conte F, Sessa A, Grünfeld J-P. Is progression of renal involvement similar in twins with ADPKD? Contrib Nephrol 1995; 115: 65-71.
12. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
13. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997; 52: 607-13.
14. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998; 78: 1165-91.
15. O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32: 976-83.
16. Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 2285-96.
17. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
18. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis 1997; 30: 311-33.
19. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-88.
20. Torres VE, Cai Y, Chen X, Wu GQ, Geng L, Cleghorn KA, Johnson CM, Somlo S. Vascular expression of polycystin-2. J Am Soc Nephrol 2001; 12: 1-9.
21. Chauvet V, Qian F, Boute N, Cai Y, Phakdeekitacharoen B, Onuchic LF, Attie-Bitach T, Guicharnaud L, Devuyst O, Germino GG, Gubler MC. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 2002; 160: 973-83.
22. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci U S A 2000; 97: 1731-6.
23. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A 2001; 98: 12174-9.
24. Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-42.
25. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-6.
26. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57: 405-13.
27. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lenz XM, Devuyst O. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11: 229-41.
28. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-11.
29. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999; 6: 233-42.
30. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu (298)->Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 26674-9.